Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.
Published By Datamonitor
|
21 Nov 2001 |
|
CommentWire
|
DiaPep277 has already shown strong trial results for type I diabetes, which is in some ways similar to LADA. This makes the new investigation seem worthwhile. Approval would provide a new treatment option for an often-misdiagnosed subcategory of diabetic patients. It would also greatly increase the market potential of the drug, by allowing access to a much larger patient population.
Published By Datamonitor
|
15 Jan 2002 |
|
CommentWire
|
Mecca Cola is in direct competition with Coca-cola, deliberately appealing to anti-US sentiments. This growing tendency for manufacturers to market themselves on a political positioning to take advantage of consumer concerns creates a loyal customer base that will not be easily swayed.
Published By Datamonitor
|
09 Jan 2003 |
|
CommentWire
|
Teva has agreed to acquire rival generics maker Ivax for $7.4 billion. If the deal goes through, Teva will become the dominant force in the generics market again, pushing Novartis' Sandoz into second place. As the gap between these top two players and the rest of the field opens up, smaller companies may struggle to keep pace and could end up being takeover targets themselves.
Published By Datamonitor
|
26 Jul 2005 |
|
CommentWire
|
Teva's biggest selling drug Copaxone has shown increased efficacy in multiple sclerosis in a high-dose phase II trial. This points to the possibility of a revival in Copaxone use, and increased competition for Biogen Idec and Elan's Tysabri if and when it is re-launched.
Published By Datamonitor
|
07 Apr 2006 |
|
CommentWire
|
Teva Pharmaceutical has received FDA approval for Azilect as a treatment for Parkinson's disease, both as initial monotherapy in early Parkinson's patients and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease. While this is good news for Teva's second proprietary drug, its true potential may only be realized once long-term neuroprotection trials are completed.
Published By Datamonitor
|
19 May 2006 |
|
Expert View
|
The savory tastes of consumers have been well catered for this month, with Productscan recording a selection of traditionally sweet products that have been given a savory makeover. These include bacon flavored chocolate and muffins with savory fillings, providing consumers with an increasing array of savory meal options.
Published By Datamonitor
|
24 Aug 2007 |
|
Expert View
|
The growing health trend has seen the release of an array of niche products, as a look at the latest launches on Productscan reveals. One such product is a new bottled water that has been created especially for diabetics, highlighting how drinks manufacturers attempt to get ahead of the competition by offering something different.
Published By Datamonitor
|
18 Jan 2008 |
|
Expert View
|
Meal options targeted at singles have been somewhat limited in the past, with most packaged foods catering for families or couples. A Norwegian store aims to change this by offering singles more choice, with a selection of limited edition meat cuts especially portioned for the singles market. As more people are living on their own, the singles market could become a bigger target in future.
Published By Datamonitor
|
20 Feb 2009 |
|
Expert View
|
Having established themselves in the European market, edge IPK and Earnix are expanding into the US property and casualty market. Both vendors have compelling offerings that should succeed in the US market, however, new regulations in the US insurance market and cost restrictions brought on by the current economic climate will not make it easy for either company.
Published By Datamonitor
|
10 Jul 2009 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.